Principal Financial Group
AKRO

Principal Financial Group’s Akero Therapeutics AKRO Stock Holding History

Principal Financial Group’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-378,858
Closed -$18M – 2186
2025
Q3 		$18M Sell
378,858
-11,316
-3% -$548K 0.01% 927
2025
Q2 		$20.8M Buy
390,174
+133,149
+52% +$6.05M 0.01% 818
2025
Q1 		$10.4M Buy
+257,025
New +$10.9M 0.01% 1237
2024
Q3 		– Sell
-9,494
Closed -$223K – 2228
2024
Q2 		$223K Sell
9,494
-4,272
-31% -$91.4K ﹤0.01% 2121
2024
Q1 		$348K Buy
13,766
+1,858
+16% +$44.6K ﹤0.01% 2066
2023
Q4 		$278K Buy
11,908
+183
+2% +$3.61K ﹤0.01% 2079
2023
Q3 		$593K Buy
11,725
+339
+3% +$15.8K ﹤0.01% 1917
2023
Q2 		$532K Buy
11,386
+726
+7% +$33.3K ﹤0.01% 1941
2023
Q1 		$408K Buy
10,660
+1,313
+14% +$58.5K ﹤0.01% 2021
2022
Q4 		$512K Buy
9,347
+2,287
+32% +$98K ﹤0.01% 1967
2022
Q3 		$241K Buy
+7,060
New +$108K ﹤0.01% 2152
2021
Q2 		– Sell
-7,709
Closed -$224K – 2599
2021
Q1 		$224K Buy
+7,709
New +$233K ﹤0.01% 2349

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Principal Financial Group's AKRO Position: Q4 2025 in Review

Principal Financial Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 378,858 shares — an estimated $18M sold.

Principal Financial Group first reported a position in AKRO in Q1 2021 and held it in 12 quarters. The position peaked at $20.8M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Principal Financial Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Financial Group sold 378,858 Akero Therapeutics shares in Q4 2025, an estimated $18M.
  • Principal Financial Group first reported a position in Akero Therapeutics in Q1 2021 and held it in 12 quarters.
  • Principal Financial Group's Akero Therapeutics position peaked at $20.8M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Principal Financial Group's 13F filing for Q4 2025, filed 2 Feb 2026.